Clinical trial
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ…
NCT00198172 · Indiana University School of Medicine, Other · Terminated
Key facts
| NCT number | NCT00198172 |
|---|---|
| Title | Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors |
| Official title | Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors |
| Lead sponsor | Indiana University School of Medicine, Other |
| Collaborators | Indiana University |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Germ Cell Tumor |
| Intervention type | Drug |
| Interventions | Cisplatin plus Epirubicin |
| Enrollment | 37 |
| Start date | Oct 1, 2000 |
| Completion | Mar 1, 2007 |
| First posted | Sep 20, 2005 |
| Last update posted | Jun 3, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: